Tilray Medical, CC Pharma, and 14U Pharma Announce Strategic Alliance with “gesund leben” Cooperation and Alliance Healthcare Deutschland to Accelerate Market Expansion and Strengthen Pharmacy Access Across Germany
Rhea-AI Summary
Tilray (Nasdaq: TLRY) announced a strategic German alliance effective April 1, 2026, joining Tilray Medical, CC Pharma, 14U Pharma and the "gesund leben" cooperation operated by Alliance Healthcare Deutschland.
The alliance leverages Alliance Healthcare's 27 logistics centers, daily supply to 10,000+ pharmacies, and the "gesund leben" network of ~3,600 member pharmacies to broaden pharmacy access, offer Rx, parallel-import discounts and Tilray's medical cannabis portfolio nationwide.
Positive
- 27 logistics centers provide nationwide distribution capacity
- Access to 10,000+ pharmacies supplied daily by Alliance Healthcare Deutschland
- "gesund leben" network adds approximately 3,600 member pharmacies
- CC Pharma gains preferred access to over 20% of German pharmacies
- CC Pharma currently supports 16,000+ pharmacies, expanding market reach
Negative
- None.
News Market Reaction – TLRY
In the Mar 12 session, TLRY declined 3.74%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Brewing partnership | Positive | +0.9% | Exclusive multi-year U.S. brewing and commercial licensing deal with Carlsberg. |
| Feb 12 | UK pharma access | Positive | -1.7% | Strategic agreement to expand UK pharmaceutical distribution via Smartway network. |
| Sep 04 | NFL co-branding | Positive | -3.0% | Broncos-branded spirits lineup extending Breckenridge–NFL partnership and promotions. |
| Aug 13 | Italy cannabis deal | Positive | +31.5% | Italian pharma partnership to broaden access to medical cannabis extracts for pain. |
| Apr 24 | Sustainability tie-up | Positive | +11.8% | Terrapin–Orvis collaboration under Terraprint environmental initiative with co-branded beer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Partnership headlines have produced mixed but often positive reactions, with several double‑digit moves, indicating that collaboration news can be a meaningful catalyst but not uniformly so.
Over the past year, Tilray has used partnerships to expand across beverages and medical cannabis. Key deals include U.S. brewing rights with Carlsberg (Feb 18, 2026) and UK pharma access via Smartway (Feb 12, 2026). Earlier, Tilray-branded beverage and cannabis alliances in Italy and with Orvis and the Denver Broncos drove notable moves, including swings of 31.51% and 11.81%. Today’s Germany pharmacy alliance extends this repeat partnership strategy in European healthcare distribution.
Key Terms
parallel import financial
medical cannabis medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DENSBORN, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- Tilray Pharma, the pharmaceutical division of Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), has announced a strategic partnership with Tilray Medical, CC Pharma, 14U Pharma, and “gesund leben” cooperation, which is operated by Alliance Healthcare Deutschland. As one of Germany’s largest pharmacy networks, Alliance Healthcare Deutschland runs 27 logistics centers across the country and supplies more than 10,000 pharmacies daily. This comprehensive distribution network is recognized as a leading support system for independent pharmacies, providing essential services, marketing resources, and purchasing benefits. It plays a vital role in ensuring effective national pharmaceutical delivery.
Effective April 1, 2026, Tilray Medical, CC Pharma, and 14U Pharma will team up to strengthen their market presence throughout Germany by offering an extensive range of products and improving pharmacy access. Through the “gesund leben” cooperation, this alliance will provide partner pharmacies with comprehensive healthcare solutions, including prescription medications (Rx), discounted medicines via parallel import, and Tilray Medical’s medical cannabis portfolio. The partnership is designed to address both B2B pharmacy requirements and B2C patient and consumer needs, granting partner pharmacies access to advantageous purchasing terms, increased product availability, and enhanced service offerings.
The “gesund leben” pharmacy cooperation comprises approximately 3,600 member pharmacies throughout Germany. Membership offers considerable benefits, including digital and priority access that enhance connectivity and expand opportunities within the network. The “gesund leben” alliance serves as a pivotal cooperative network in the German pharmacy sector, delivering added value through competitive purchasing terms, innovative operational efficiency services, intelligent solutions for increasing customer traffic and sales, and customized support for its members.
Rajnish Ohri, President, International, Tilray Brands, stated, “Germany remains one of the most important and dynamic healthcare markets in Europe. By bringing Tilray Medical, CC Pharma, and 14U Pharma together through this partnership, we are stronger together — scaling our German operations, expanding pharmacy access, and creating an even more powerful platform for long-term growth. This collaboration strengthens our ability to serve pharmacies, patients, and consumers nationwide, while setting the stage for continued expansion across the German market.”
CC Pharma is one of two parallel import companies chosen as partners by Alliance Healthcare Deutschland, highlighting Tilray’s strong reputation in German pharmaceutical distribution. This partnership gives CC Pharma preferred access to over
Mathias Bossen, Managing Director of CC Pharma, commented, “Our long-standing partnership with Alliance Healthcare Deutschland is being taken to a new level through this strategic cooperation. By combining our strengths and expertise, we are setting new standards in access, service, and innovation for pharmacies and patients across Germany.”
This partnership further reinforces Tilray’s commitment to building a scaled, integrated healthcare platform in Germany, leveraging its pharmaceutical distribution leadership through CC Pharma and its expanding medical cannabis footprint through Tilray Medical.
About Alliance Healthcare Deutschland and GEHE
Alliance Healthcare Deutschland and GEHE move health: safely, reliably and quickly. Alliance Healthcare Deutschland GmbH, based in Frankfurt am Main, is a member of The Boots Group and, with its two wholesale brands Alliance Healthcare® Deutschland and GEHE® as well as the strong pharmacy cooperation “gesund leben”, is one of the most important healthcare providers for pharmacies and pharmaceutical manufacturers in Germany. With a modern network and future-proof services, the full-service pharmaceutical wholesaler with 29 locations, together with its partners, guarantees the nationwide supply of medicines and healthcare services. The focus is on sustainable, trustworthy and holistic healthcare in Germany, so that everyone can live healthier and more fulfilling lives. #wemovehealth
www.alliance-healthcare-gehe.de
About “gesund leben”
The important pharmacy cooperation “gesund leben” strengthens pharmacies sustainably, economically and structurally, while taking responsibility for the healthcare of millions of people. The cooperation supports its approximately 3,600 partner pharmacies with comprehensive, forward-looking services in the areas of marketing, health counselling, digitalisation, human resources management and continuing education, as well as operational processes and finance. With this strong service portfolio, we enable our partners to offer innovative customer approaches and new healthcare services. The focus is always on people and their health.
About CC Pharma
CC Pharma is a leading pharmaceutical distributor in Germany, serving pharmacies nationwide with a broad portfolio of branded and generic medicines. As part of Tilray Brands, CC Pharma combines local market expertise with the scale, discipline, and strategic resources of a global organization.
For more information on CC Pharma, visit www.cc-pharma.com
About 14U Pharma
14U Pharma, a subsidiary of CC Pharma, is a Germany-based pharmaceutical company that specializes in rebate contracts and is focused on innovative healthcare solutions and patient-centered product development.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand.
About Tilray Brands
Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms.
Forward-Looking Statements
Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication, , and such assumptions may prove to be incorrect. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, anticipated ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws.
For further information, please contact:
CC Pharma GmbH – In den Feldern 2 – 54570 Densborn – Germany
Verena Meiers: marketing@cc-pharma.de
Tilray Brands Media: news@tilray.com
Investors: investors@tilray.com
